Modulation of the RNA‐sensing RIG/MAVS pathway bypasses resistance to hypomethylating agents in acute myeloid leukemia
HemaSphere · 2026-11 · 10 (11)
DOI: 10.1002/hem3.70523 ↗Abstract
Abstract DNA hypomethylating agents (HMAs) such as 5‐azacytidine (5‐AZA) are a cornerstone in the treatment of acute myeloid leukemia (AML), but development of resistance represents a major clinical challenge. Apart from epigenetic reprogramming of malignant cell clones, therapy with HMA is increasingly recognized to facilitate antineoplastic immunity, yet the relevance of these molecular mechanisms in AML remains poorly defined. Here, we show that AML cell‐intrinsic sensing of aberrant RNA via the innate receptor system retinoic acid‐inducible gene I (RIG‐I)/mitochondrial antiviral‐signaling protein (MAVS) is essential for the therapeutic activity of HMAs. In human and murine AML cell lines, HMA treatment induced robust RIG‐I/MAVS pathway activation and subsequent Type I interferon (IFN‐I) release. HMA enhanced transcriptional activity of endogenous retroviral (ERV) elements that readily bound to the RIG‐I receptor. Analysis of a small series of patient samples linked treatment response to elevated gene expression of ERV and RIG‐I/MAVS pathway components in CD34 + cells including AML blasts. AML‐intrinsic genetic ablation of MAVS or RIG‐I abrogated the HMA treatment effects in mice by interfering with host IFN‐I signaling and subsequent expansion and accumulation of activated T cells. Acquired HMA resistance was associated with ERV suppression and blunted RIG‐I/MAVS signaling. Treatment with all ‐trans retinoic acid (ATRA) restored RIG‐I pathway activity and antileukemic response in mice bearing HMA‐resistant AML. Our findings not only delineate a critical link between epigenetic modulation and innate immune activation in AML but also provide a rationale for targeting the RIG‐I/MAVS RNA‐sensing pathway to enhance antileukemic immunity and bypass epigenetic resistance to HMA.
EUVIMED